CompletedPhase 2

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Started 1978-01

Plain-language summary

To determine whether deferoxamine prevented the complications of transfusional iron overload.

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Males and females, 5 years or older, with transfusional hemochromatosis.

NCT IDNCT00000595

SponsorNational Heart, Lung, and Blood Institute (NHLBI)

Sponsor typeNIH

Study typeINTERVENTIONAL